1499:-
Uppskattad leveranstid 7-11 arbetsdagar
Fri frakt för medlemmar vid köp för minst 249:-
This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.
- Format: Pocket/Paperback
- ISBN: 9783838343532
- Språk: Engelska
- Antal sidor: 256
- Utgivningsdatum: 2011-05-10
- Förlag: LAP Lambert Academic Publishing